(Source: Herantis Pharma Oyj) Herantis Pharma receives orphan designation in USA for CDNF for treatment of ALS Herantis Pharma Plc Company release 11 July 2016 at 9:00 am The United States Food and Drug Administration FDA has granted orphan designation for Herantis Pharma Plc's ('Herantis') CDNF for treatment of amyotrophic lateral sclerosis (ALS). Earlier this year the European Medicines Agency EMA issued a corresponding positive decision. 'We are very pleased with the world's leading medicines agencies reaching independently the same conclusion on the strength of the preclinical evidence', says Dr. Henri Huttunen, Chief Scientific Officer of Herantis. 'This positive decision by the FDA...
↧